Infertility
FRIDAY, NOVEMBER 11TH, 2016 HALL A |
|
08:30-10:00 | PCOS |
Capsule | PCOS: The most common endocrine disorder (5-10%) may be due to a combination of genetic and environmental factors that are possibly worsened by epigenetic factors, industrial endocrine disruptors or obesity exposures during the prenatal period |
Chairpersons | Zion Ben-Rafael, Israel Jerome F. Strauss III, USA |
08:30-09:00 | Hormonal aspect of PCOS Phillippe Bouchard, France |
09:00-09:30 | PCOS: Is there a preferred stimulation protocol for IVF? Basil C. Tarlatzis, Greece |
09:30-10:00 | Genetics of PCOS Jerome F. Strauss III, USA |
Session | Industry Session |
12:00-13:40 | OVARIAN STIMULATION |
Capsule | COH is a crucial step in ART. What is the place of AMH in the diagnosis and hCG in reaching optimal results? |
Chairpersons | Nick S. Macklon, UK Fady I. Sharara, USA |
12:10-12:40 | Role of hCG in ovarian stimulation Christophe Blockeel, Belgium |
12:40-13:10 | hCG versus LH Manuela Simoni, Italy |
13:10-13:40 | Where AMH fits into controlled ovarian stimulation Frank J.M. Broekmans, The Netherlands |
14:30-16:00 | ADENOMYOSIS |
Capsule | For too long Adenomyosis was difficult to diagnose, classify, and treat. Did we overcome all these issues now? |
Chairpersons | Felice Petraglia, Italy Victor Gomel, Canada |
14:30-14:50 | Are Adenomyosis and Endometriosis the same entity? Stephan Gordts, Belgium |
14:50-15:15 | Classification of Adenomyosis Gregoris Grimbizis, Greece |
15:15-15:35 | Management of Adenomyosis Felice Petraglia, Italy |
15:35-16:00 | Different surgical options of Adenomyosis Gregoris Grimbizis, Greece |
16:30-18:00 | MECHANICAL INFERTILITY |
Capsule | Mechanical factors that affect implantation are not common but lend themselves to treatment |
Chairpersons | Felice Petraglia, Italy Stephan Gordts, Belgium Mattheos Fraidakis, Greece |
16:30-16:50 | Implications of Adenomyosis for fertility Velja Mijatovic, The Netherlands |
16:50-17:35 | Debate: Is Exploring the uterine cavity via ultrasound enough? Yes: Andrea Tinelli, Italy No: Mark Emanuel, The Netherlands Discussion |
17:35-18:00 | Caution: Endometrioma surgery can be very deleterious for the ovarian reserve Jacques Donnez, Belgium |
SATURDAY, NOVEMBER 12TH, 2016 HALL A |
|
08:30-10:00 | THE ENDOMETRIUM: WHAT IS NEW? |
Capsule | More forms of infertility will be subjected to treatment as the endometrium, the most neglected organ in reproduction, is revealing its secrets |
Chairpersons | Frank Broekmans, The Netherlands Jacques Donnez, Belgium |
08:30-08:50 | Embryo-Endometrium dialogue Nick S. Macklon, UK |
08:50-09:15 | The emerging role of junctional zone in endometrium formation and implantation potential Stephan Gordts, Belgium |
09:15-09:35 | Biomarkers or genetic tests for endometrial receptivity Jose Horcajadas, Spain |
09:35-10:00 | Endometrial regeneration: Stem cell therapy in Asherman Syndrome and Atrophic Endometrium Antonio Pellicer, Spain |
10:20-11:50 | FERTILITY PRESERVATION FOR CANCER PATIENTS |
Capsule | Cancer patients should be informed of options for fertility preservation and future reproduction prior to cancer treatment (ASRM). Reproduction in the context of cancer raises a number of clinical and ethical issues |
Chairpersons | Norbert Gleicher, USA Attila Vereczkey, Hungary |
10:20-10:40 | New frontier in vitrification for human oocytes and embryos Masashige Kuwayama, Japan |
10:40-11:05 | Fertility preservation in the female: What are the prerequisites for success? Marie M. Dolmans, Belgium |
11:05-11:25 | Fertility preservation: What is the best – oocyte vitrification or tissue freezing? Antonio Pellicer, Spain |
11:25-11:50 | Fertility preservation for cancer patients: Are we over-using the technique? Kirsten L. Tryde Macklon, Denmark |
12:10-13:40 | FERTILITY PRESERVATION : WHERE SHOULD WE GO FROM HERE? |
Capsule | Fertility preservation is often possible in cancer patients. However, in order to close the large gap between the need and the actual usage it is pertinent to produce interdisciplinary guidelines that will call upon every oncologist to discuss the options with every patient of reproductive age |
Chairpersons | Marie M. Dolmans, Belgium Kirsten L. Tryde Macklon, Denmark |
Fertility preservation: Balancing risks versus benefits Annelies Bos, The Netherlands |
|
Is there an ideal guideline? Willianne Nelen, The Netherlands |
|
How to increase awareness among oncologists: A gynecologist point of view? Marie M. Dolmans, Belgium |
|
Physicians’ perspective on fertility preservation in patients with cancer: Results of a survey performed by IVF Worldwide Zeev Shoham, Israel |
14:30-16:00 | OVARIAN AGING |
Capsule | Ovarian aging is the main reason for ART failures |
Chairpersons | Rene Frydman, France Stephan Gordts, Belgium Attila Vereczkey, Hungary |
14:30-14:50 | Assessment of ovarian aging Frank J.M. Broekmans, The Netherlands |
14:50-15:10 | Treatment of poor responders Zion Ben-Rafael, Israel |
15:10-15:30 | When to revert to egg donation Pedro Barri, Spain |
15:30-16:00 | SPECIAL LECTURE: Update on uterine transplantation and pregnancy outcome Mats Brännstrom, Sweden |
16:30-18:00 | RTD ON BURNING CLINICAL ISSUES IN INFERTILITY WITH PANELISTS AND AUDIENCE INTERACTION |
Moderators | Zion Ben-Rafael, Israel Bart C.J.M. Fauser, The Netherlands |
Discussants | Rene Frydman, France Nick S. Macklon, UK Simon Fishel, UK Jacques Cohen, USA Manuela Simoni, Italy |
Questions | 1. Does ovarian stimulation for IVF affect oocyte / embryo quality? 2. Is freeze all embryos a realistic strategy for all IVF patients? Who is doing it? 3. Does GnRH agonist trigger for final oocyte maturation improve IVF outcome 4. Current status of androgen supplementation to FSH ovarian stimulation for IVF 5. Current status of LH / hCG supplementation to FSH ovarian stimulation for IVF 6. All ovulation induction in PCOS should be replaced by IVF (the only way to effec-tively reduce multiple pregnancies) 7. AUGMENT by OvaScience – what’s the evidence? what do practitioners need to know about what is being injected? 8. PGS- clinical evidence, risk of litigation 9. Should mosaic embryos be transferred? 10. What KPI’s (Key Performances Indicators) should be used in an IVF lab? 11. In 2017, should virtually all women undergoing IVF have single embryo transfer? Who has achieved it? |
SUNDAY, NOVEMBER 13TH, 2016 HALL A |
|
08:30-10:00 | PERSONALIZED MEDICINE IN ACTION |
Chairpersons | Dominique de Ziegler, France Zion Ben-Rafael, Israel |
08:30-09:00 | Personalization of medicine: Is fertility a good example? Bart C.J.M. Fauser, The Netherlands |
09:00-09:30 | When should IVM be used Dominique de Ziegler, France |
09:30-10:00 | The role of Progesterone revisited: A personal perspective Phillipe Bouchard, France |
10:30-12:00 | HIGHLY CITED DUTCH RESEARCH IN REPRODUCTIVE MEDICINE |
Capsule | Three university medical centers from The Netherlands belong to the most cited research centers in Clinical Reproduction. Young members from these units will present their own work and put this in the larger perspective of the overall focus of the team |
Chairpersons | Bart C.J.M. Fauser, The Netherlands Zion Ben-Rafael, Israel |
10:30-10:50 | Multi-follicular ovaries, presence and growth in health and disease Marieke Verhoeven, (on behalf of Professor Lambalk team), VU University Medical Center, Amsterdam, The Netherlands |
10:50-11:15 | “Genetics of PCOS” Yvonne V. Louwers, (on behalf of Professor Laven team), Erasmus University Medical Center, Rotterdam, The Netherlands |
11:15-11:35 | Androgens and cardiovascular risk in women with reproductive dysfunction Nadine Daan, (on behalf of Professor Fauser team) UMC Utrecht, The Netherlands |
11:35-12:00 | Endometrial implantation Robert P. Berkhout, (on behalf of Professor Repping team) AMC Amsterdam, The Netherlands |
FRIDAY, NOVEMBER 11TH, 2016 HALL B |
|
08:30-10:00 | LABORATORY WORK CONTRIBUTING TO SUCCESS (I) |
Capsule | Quality control and risk management are cornerstones in IVF success |
Chairpersons | Laura Rienzi, Italy Jacques Cohen, USA |
08:30-08:50 | TQM (Total quality management): Why it matters? Edith Coonen, Netherlands |
08:50-09:15 | Quality control in ART Rita Vassena, Spain |
09:15-09:35 | In-vitro follicular culture Evelyn Telfer, UK |
09:35-10:00 | Relevance of embryo competence for successful IVF, and role of GCSF Bart C.J.M. Fauser, The Netherlands |
10:20-11:50 | LABORATORY WORK CONTRIBUTING TO SUCCESS (II) |
Capsule | How laboratory work can better results? |
Chairpersons | Manuela Simoni, Italy Rita Vassena, Spain |
10:20-10:40 | What key performance indicators (KPI’s) should be used in an IVF lab? Simon Fishel, UK |
10:40-11:05 | How to improve embryo quality in the IVF lab Laura Rienzi, Italy |
11:05-11:25 | What is risk and how do you assess it? Edith Coonen, Netherlands |
11:25-11:50 | Selecting the right sperm for ICSI Laura Rienzi, Italy |
12:10-13:40 | BREAKING NEWS – ON THE MEANING OF UNEUPLOIDY |
Capsule | Research and innovation is the only way forward |
Chairpersons | Simon Fishel, UK Magdelena Zernicka-Goetz, UK |
12:10-12:30 | Building the embryo: Plasticity and fate Magdelena Zernicka-Goetz, UK |
12:30-12:55 | Development of the human embryo beyond day 7 in a dish Marta N. Shahbazi, UK |
12:55-13:15 | What can these studies teach us about PGS? Norber Gleicher, USA |
13:15-13:40 | Precision medicine in assisted conception: A multi-center observational treatment cohort study of the annexin A5 M2 haplotype as a biomarker for antithrombotic treatment to improve pregnancy outcome Simon Fishel, UK |
14:30-16:00 | GENE EDITING: FROM BENCH TO CLINIC AND BACK TO MORATORIUM? |
Capsule | “Genome engineering” refers to the process of targeted modification of the genome. Like a “search mode” Cas9 can guide to specific site of intricate genomes by string of short RNA. Gene Editing of human germline with CRISPR/Cas9 technology can eventually transform medicine, basic research and biotechnology. How does it work? Should it be banned from use on gametes? |
Chairpersons | Jacques Cohen, USA Anthony C.F. Perry, UK |
14:30-15:00 | Technical aspects of gene editing in gametes and embryos Anthony C.F. Perry, UK |
15:00-15:30 | Possible applications of gene editing in gametes and embryos Rita Vassena, Spain |
15:30-16:00 | Ethical aspects and moratorium on gene editing in embryos Heidi Mertes, Belgium |
16:30-18:00 | OVARIAN STIMULATION III Organized by The Turkish Society of Reproductive Medicine |
Chairperson | Gurkan Uncu, Turkey |
16:30-16:50 | Monitoring ART cycles: What is the additional value of endocrine testing? Barış Ata, Turkey |
16:50-17:15 | Individualized ovarian stimulation for ART Gurkan Bozdağ, Turkey |
17:15-17:35 | Adjuvants to ovarian stimulation for ART Gurkan Uncu, Turkey |
17:35-18:00 | Monitoring the luteal phase and individualized luteal support: Fact or fiction? Ahmet Zeki Isik, Turkey |
SATURDAY, NOVEMBER 12TH, 2016 HALL B |
|
08:30-10:00 | ALTERNATIVE PERSPECTIVES ON INFERTILITY CARE |
Capsule | The increasing need for quality reproductive treatments dictates involvement of patient’s organizations, societies and states in the regulation of the services |
Chairpersons | Bart C.J.M. Fauser, The Netherlands Kamal Ahuja, UK |
08:30-08:50 | What patient organizations can do for infertile couples? Elin Einarsdottir, Iceland |
08:50-09:15 | Context based infertility care Jan A.M. Kremer, The Netherlands |
09:15-09:35 | Infertility and its implications for couples and children Lone Schmidt, Denmark |
09:35-10:00 | From cross-border reproductive care to treatment at home: a turning of the tide? Zeynep Gurtin & Kamal Ahuja, UK |
Session | LABORATORY WORK CONTRIBUTING TO SUCCESS (III) |
Capsule | Several recent and futuristic technologies which are in the forefront of laboratory research, including Mitochondrial Replacement Therapy (MRT) to avoid diseases transmission (which was recently approved in the UK for clinical use), nuclear transplantation or spindle transfer, mitochondrial supplementation and germ cell lines promise that innovation will keep fueling our field |
Chairpersons | Simon Fishel, UK Barbara Wirleitner, Austria |
10:20-10:40 | MRT (Mitochondrial Replacement Therapy) and PGD as a first line treatment for mitochondrial disorders Jacques Cohen, USA |
10:40-11:05 | Potential of germ line stem cells Evelyn Telfer, UK |
11:05-11:30 | Epigenetics in reproduction Rebecca Painter, The Netherlands |
11:30-11:50 | Laboratory instrumentation, data handling and quality control Jacques Cohen, USA |
12:10-13:40 | METHODS FOR EMBRYO SELECTION: TOWARDS SET FOR ALL |
Capsule | Better selection methods might affect the rate of adoption of SET for IVF treatment however current methods to assess the preimplantation embryos like morphology, time lapse, PGS or markers are alone far from perfection. Can a combination of methods secure a better selection and implantation rate? |
Chairpersons | Rene Frydman, France Jean Michel Foidart, France |
12:10-12:30 | Time-Lapse: Improved culture or just an expensive toy? Thomas Ebner, Austria |
12:30-12:55 | What to do with embryos with reversed cleavage? Diana Stein, Israel |
13:20-13:40 | The pros and cons of embryo selection Thorir Hardarson, Sweden |
14:30-16:00 | PGS: A FRIEND OR A FOE OF THE PATIENTS? |
Capsule | The debate is more acute now: While the technique seems to be improving the question now is can universal PGS improve the results of ART or worsen them? |
Chairpersons | Luca Gianaroli, Italy Norbert Gleicher, USA |
14:30-14:55 | Optimizing embryo biopsy techniques Simon Fishel, UK |
14:55-15:15 | Blastocoel analysis for PGS and the potential clinical value of mitochondrial screening assays Luca Gianaroli, Italy |
15:15-16:00 | Debate: Overcoming the technical gaps will lead to PGS to all embryos… It’s only a matter of time Yes: Jacques Cohen, USA No: PGS causes more damage than benefit Norbert Gleicher, USA Discussion |